Literature DB >> 1350971

The utility of spirometry in the diagnosis of reversible airways obstruction.

H R Smith1, C G Irvin, R M Cherniack.   

Abstract

Patients with suspected reversible airways obstruction (RAO) sometimes report subjective benefit after bronchodilator treatment despite no objective spirometric improvement. One possible explanation for this is improvement in volume-related or plethysmographic parameters in the absence of spirometric improvement. One hundred patients with RAO were assessed before and after inhaled bronchodilator to determine the prevalence of improvement by plethysmographic parameters in the absence of improvement in spirometric parameters. Spirometry alone (FEV1, FVC, and FEF25-75%) identified reversibility of airflow limitation in 82 patients. Reversibility was identified by body plethysmography (specific conductance [SGaw], thoracic gas volume [TGV], and isovolume maximum expiratory flow rates [IVMEF]) in 15 of the remaining patients. The percent predicted FEF25-75% at baseline was higher in patients who required plethysmography to identify reversibility, but could not be used to predict the lack of a spirometric response for any individual patient. We conclude that spirometry alone fails to identify reversibility in approximately 15 percent of patients, and that most of these patients can be identified by additional plethysmographic measurements of volume-related parameters. At any one point in time, multiple tests must be used together to adequately identify the majority of patients with reversible airways obstruction. Improvement in volume-related parameters may explain why some patients with RAO improve subjectively with bronchodilators but show no spirometric improvement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350971     DOI: 10.1378/chest.101.6.1577

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

Review 1.  Asthma outcomes: pulmonary physiology.

Authors:  Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

2.  Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?

Authors:  Mariëlle E A C Broeders; Johan Molema; Wim C J Hop; Niek A Vermue; Hans T M Folgering
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

Review 3.  Therapeutic Potential of Chungsangboha-tang for the Treatment of Asthma: A Review of Preclinical and Clinical Studies.

Authors:  Sung-Woo Kang; Kwan-Il Kim; Youngmin Bu; Beom-Joon Lee; Hee-Jae Jung
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.